DNA Nanostructure Signal Amplification in Immunoassays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lateral flow immunoassays (LFAs) are not suitable for detecting low analyte concentrations in the picomolar regime due to limited sensitivity, resulting in high rates of false-negative results, and are not accessible in developing worlds due to infrastructure and resource limitations.
Innovation Solution
A polynucleotide-based nanostructure with a predefined number of binding sites is used to amplify the detection signal in immunoassays, allowing for improved sensitivity and reliability by linearly amplifying the detection signal, enabling the detection of lower analyte concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional lateral flow immunoassays use single detectable labels per analyte, then the device complexity remains low and ease of operation is maintained, but the measurement precision and reliability are insufficient for detecting low analyte concentrations in the picomolar regime
Solution Approach 1:
The labeling system is segmented into modular components: a polynucleotide-based nanostructure core with multiple binding sites, and multiple detectable labels that can be attached to these sites. This segmentation allows each component to be optimized independently while achieving high measurement precision through the collective signal from multiple labels.
Solution Approach 2:
The invention uses composite materials by combining polynucleotide-based nanostructures with detectable labels to create a hybrid labeling system. This composite structure integrates the specific binding capability of polynucleotides with the detectable signal properties of the labels, achieving both high sensitivity and reliable detection of low analyte concentrations.
2Reliability
If conventional LFAs are used in the picomolar regime, then the device simplicity and low cost are maintained, but the reliability decreases with high rates of false-negative results
Solution Approach 1:
Multiple detectable labels are merged onto a single polynucleotide-based nanostructure that binds to one analyte molecule. This merging creates a signal amplification effect where the combined signal from multiple labels enables reliable detection even when the quantity of analyte is very low in the picomolar regime, eliminating false-negative results.
3Measurement precision
If multiple detectable labels are attached to each analyte binding event, then the measurement precision and detection sensitivity are improved, but the manufacturing precision requirements increase for controlling the number of labels per nanostructure
Solution Approach 1:
The polynucleotide-based nanostructure is pre-designed with a defined number of binding sites before the labeling process. This preliminary structuring allows for controlled attachment of a specific number of detectable labels, ensuring that each nanostructure carries a precise and reproducible signal intensity, which is critical for quantitative analysis accuracy.
Solution Approach 2:
The invention controls the number of detectable labels per nanostructure by adjusting parameters such as label-to-nanostructure ratio, incubation time, and binding conditions. By optimizing these parameters, the manufacturing process achieves precise control over label attachment, enabling reliable quantitative analysis while maintaining measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polynucleotide-based nanostructure enhances the sensitivity of immunoassays, allowing for the reliable detection of low analyte concentrations and providing a quantitative analysis without the need for calibration curves, thus improving diagnostic capabilities at an early stage of diseases.
Implementation Method 1
The polynucleotide-based nanostructure has a predefined number N>1 of second binding sites, each second binding site being configured to bind a detectable label
Data Source
AI summary
The invention relates to a labeling DNA nanostructure for providing a signal amplifying detectable label in immunoassays, a test device, in particular a lateral flow test device, which comprises the labeling DNA nanostructure, a method for producing the labeling DNA nanostructure or the test device.